SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as community members express strong conviction and a shared belief in the project's long-term potential. The community emphasizes the importance of unity and hard work, especially during market downturns. Many community members are excited about the potential of OG memes.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy (MSTR) is trending as the price fluctuates with Bitcoin's volatility, sparking debates about its valuation and future prospects. The community is actively discussing potential support levels, Saylor's next moves, and whether the stock's correlation with Bitcoin makes it a worthwhile investment or a risky bet. Bearish sentiment seems to be gaining traction amid concerns about debt and market conditions.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy`s Co

Wendy's is trending due to a mix of factors including recent earnings, shareholder returns, and community speculation about a turnaround. Community members are actively discussing its valuation relative to peers and the potential impact of international growth and new menu items, particularly the 'Tendys' chicken campaign, on the company's performance. Despite some concerns around debt and sales figures, many see the current price as an opportunity, with discussions around potential buyouts and a possible meme stock rally.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending due to its acquisition of Hawthorne Airport near Los Angeles, stirring both excitement about strategic positioning and concerns regarding cash expenditure. The community is actively debating the implications of this move, including potential partnerships with companies like Tesla, along with management's capital allocation decisions and timeline for piloted flights.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor ($OPEN) is trending amid discussions around its earnings report and a strategic shift toward becoming a software and AI-driven company, sparking mixed reactions. The warrant distribution is a key talking point, with some viewing it as a potential catalyst for a short squeeze, while others see it as a red flag indicating desperation. Community members are also debating the influence and track record of prominent figures associated with the stock.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is trending as investors weigh recent analyst upgrades and price target adjustments against mixed sentiment surrounding Q3 earnings and potential competition from Amazon. The community is actively discussing the company's growth prospects, particularly in CTV, with some viewing the current price as a buying opportunity amid broader market volatility. Discussions also focus on the potential impact of a new CRO and the effectiveness of AI-driven initiatives on future revenue.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as investors debate its next move, with the tug-of-war around the $100K level intensifying. Community discussions range from potential government shutdown impacts and influence of political figures like Trump to concerns about manipulation and comparisons to other asset bubbles like AI. Despite the uncertainty, some bulls remain optimistic, pointing to long-term fundamentals, diminishing supply, and potential institutional support.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

Affirm Holdings' stock is trending due to a strong fiscal first-quarter earnings report that exceeded expectations and boosted the company's fiscal 2026 outlook, leading to praise from analysts. Community discussions revolve around the potential for further gains, partnership extension with Amazon, and overall BNPL momentum, though some traders express caution about the market's sell-off mode and potential for a pullback.

Sweetgreen, Inc. owns and operates a chain of salad restaurants. It offers drinks, sides, local bowls, salads, plates, and warm bowls. The company was founded by Nicolas Jammet, Jonathan Neman, and Nathaniel E. Ru in November 2006 and is headquartered in Los Angeles, CA.

Sweetgreen Inc - Ordinary Shares - Class A

Sweetgreen ($SG) is trending amidst discussions of disappointing earnings and lowered guidance, leading to a significant stock drop. The community is debating the company's profitability, expansion strategy, and management effectiveness, with some speculating about a potential acquisition or bankruptcy. Despite the concerns, some investors believe $SG is oversold and represents a long-term value opportunity, particularly given its robotic kitchen technology.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

Recent news regarding lowered 2026 guidance and a strategic acquisition of a skincare brand, RHODE, seems to be driving volatility in e.l.f. Beauty. The community is actively discussing the impact of the acquisition, potential sales increases, and revised price targets from analysts. Some traders are eyeing oversold conditions and potential bounces, while others express concerns about insider selling and downside risks.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>QOL Medical will buy Evoke for $11 per share, representing a premium of about 140% from the stock’s closing price on Monday.&nbsp;</li><li>The transaction has been approved by the boards of both companies and is expected to close by the end of 2025.</li><li>QOL Medical intends to finance the transaction with cash on hand. &nbsp;</li></ul>Shares of Evoke Pharma, Inc. (EVOK) more than doubled on Tuesday after the company said that it has entered into a definitive agreement to be acquired by privately-held QOL Medical for $11 per share.The purchase price represents a premium of about 140% from the stock’s closing price on Monday.Following the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/04/3180135/28255/en/Evoke-Pharma-Enters-into-Definitive-Agreement-to-Be-Acquired-by-QOL-Medical.html">announcement</a>, <a href="https://stocktwits.com/symbol/EVOK">EVOK shares</a> shot up 134% by Tuesday afternoon to hit $10.72 as of the time of writing, but still remained below the deal price.<h2 class="st-heading-2">Terms Of The Deal</h2>Florida-based QOL Medical will initiate a tender offer to acquire all outstanding shares of Evoke through a subsidiary. Once the tender offer is completed, a unit of QOL Medical will merge with Evoke.&nbsp;The transaction has been approved by the boards of both companies and is expected to close by the end of 2025. QOL Medical intends to finance the transaction with cash on hand.Evoke noted that the deal reflects the strategic value of Gimoti, the company’s nasal spray for the treatment of symptoms of acute and recurrent diabetic gastroparesis in adults. Diabetic gastroparesis is a chronic condition where the stomach takes too long to empty due to nerve damage caused by poorly controlled diabetes. Symptoms include nausea, vomiting, and bloating, among others.The gastric delay caused by gastroparesis can compromise absorption of orally administered medications, and until approval of Gimoti, treatment was available only in oral and injectable formulations.“GIMOTI strengthens our GI portfolio and advances our mission to support patients living with rare and underserved gastrointestinal conditions,” QOL Medical CEO Derick Cooper said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around EVOK jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:621/59;" src="data:image/png;base64,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" width="621" height="59" alt="EVOK's Sentiment Meter and Message Volume as of 1:29 p.m. ET on Nov. 4, 2025 | Source: Stocktwits"><figcaption>EVOK's Sentiment Meter and Message Volume as of 1:29 p.m. ET on Nov. 4, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user applauded the stockholders.<stembedurl>https://stocktwits.com/erb71/message/634823600</stembedurl>EVOK stock is up by 143% this year and by 87% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/stellantis-recalls-over-320000-jeep-plug-in-hybrids-in-us-over-fire-risk/cL28S1PR36n">Stellantis NV Recalls Over 320,000 Jeep Plug-In Hybrids In US Over Fire Risk</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

EVOK Stock Doubled In Value Today Post QOL Medical Deal, But Still Fails To Hit $11 Mark

Evoke noted that the deal reflects the strategic value of Gimoti, the company’s nasal spray for the treatment of symptoms of acute and recurrent diabetic gastroparesis in adults.

Equity

Shareholder Alert: The Ademi Firm investigates whether Evoke Pharma Inc. is obtaining a Fair Price for its Public Shareholders

Shareholder Alert: The Ademi Firm investigates whether Evoke Pharma Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm investigates whether Evoke Pharma Inc...

EVOK Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Evoke Pharma, Inc. is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Evoke Pharma, Inc. (NASDAQ: EVOK) to QOL Medical, LLC for $11.00 per share in cash is fair to Evoke shareholders...

Evoke Pharma's stock soared 168% on Wednesday after the company announced it had received a new U.S. patent that could extend the market life of Gimoti, its nasal spray treatment for gastroparesis.The patent, once issued, would provide Evoke with added protection through December 2036, covering the use of the drug in patients with moderate to severe symptoms of the condition.&nbsp;Gastroparesis impairs the stomach’s ability to empty, often rendering oral medications less effective.&nbsp;Evoke plans to list the new patent in the FDA’s Orange Book, which would extend exclusivity for Gimoti beyond its current timeline.The news comes alongside improving financials. In the first quarter of 2025, Evoke generated approximately $3.1 million in product sales, nearly doubling its revenue from the same period a year earlier.&nbsp;The company reported a net loss of $1.3 million, which&nbsp;translates to a loss of $0.51 per share, representing an improvement from the $1.6 million loss, or $2.09 loss per share, in the same quarter last year.Spending also ticked up, driven mainly by higher fees and profit-sharing with Eversana, its commercial partner.&nbsp;Operating expenses totaled $4.4 million, up from $3.2 million a year earlier.As of March 31, Evoke had $12.6 million in cash.&nbsp;Based on its current plans, it expects to carry operations into the second quarter of 2026.&nbsp;The company is also sticking to its 2025 sales goal of $16 million, which would be a 60% increase from last year if current trends continue.On Stocktwits, retail sentiment for Evoke was ‘extremely bullish’ amid ‘extremely high’ message volume.One user mentioned buying 100 lots of Evoke’s stock and said they were waiting for a potential move to cover.&nbsp;<stembedurl>https://stocktwits.com/mikefromclt/message/620413256</stembedurl>Another user expressed a bullish outlook as well, saying they were fully loaded on the stock and planned to hold their position into the next session.<stembedurl>https://stocktwits.com/stocksweets/message/620411085</stembedurl><a href="https://stocktwits.com/symbol/EVOK">Evoke’s stock</a> has risen 56.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Evoke Pharma (EVOK) received a new U.S. patent that could extend the market life of Gimoti/ Photo credit: Getty Images

Evoke Pharma Stock Skyrockets On Patent For Nasal Spray That Eases Stomach Delays; Retail Bulls Pile In

The newly allowed patent covers the use of Gimoti in patients with moderate to severe gastroparesis and is expected to extend market exclusivity through 2036. 

Evoke shares drop 15% as loss widens despite revenue growth

Evoke expects earnings to exceed market expectations, shares jump

Monte Rosa Therapeutics Inc. (<a class="mention" data-mention="$GLUE" data-symbol-id="GLUE" href="https://stocktwits.com/symbol/GLUE" target="_blank">$GLUE</a>)<figure class="image"><a href="https://stocktwits.com/symbol/GLUE"><img style="aspect-ratio:1284/287;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132438_e581646ba1.png" alt="Screenshot 2024-10-28 132438.png" width="1284" height="287"></a><figcaption>Monte Rosa Therapeutic's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Shares of Monte Rosa Therapeutics surged over 130% on Monday, reaching a two-year high of $12.15 after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/glue-stock-enthralls-retail-with-novartis-licensing-deal/cJ2rnM9RJW">announcing an exclusive global licensing agreement with Novartis AG ($NVS).</a>&nbsp;The collaboration focuses on developing innovative treatments for immune-related conditions, particularly MRT-6160, an oral drug designed to inhibit the degradation of VAV1, a key signaling protein for T and B cell receptors.&nbsp;As part of the agreement, Novartis will pay $150 million upfront for exclusive worldwide rights to MRT-6160 and other VAV1-targeting molecular glues, with Monte Rosa eligible for up to $2.1 billion in milestones and tiered royalties on international sales.Retail sentiment on Stocktwits surged to ‘extremely bullish’ (97/100) with ‘extremely high’ (97/100) message volume.Evoke Pharma Inc. (<a class="mention" data-mention="$EVOK" data-symbol-id="EVOK" href="https://stocktwits.com/symbol/EVOK" target="_blank">$EVOK</a>)<figure class="image"><a href="https://stocktwits.com/symbol/EVOK"><img style="aspect-ratio:1282/282;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132459_473ee74b09.png" alt="Screenshot 2024-10-28 132459.png" width="1282" height="282"></a><figcaption>Evoke Pharma's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Evoke Pharma’s shares were up over 30% on Monday following its presentation of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/evoke-pharma-stock-spikes-higher-on-study-data/cJ2rllaRJO">positive data for its lead drug</a>, Gimoti, as a treatment option for diabetes gastroparesis.The company ranked among the top 10 trending stocks on Stocktwits, secured the second spot for most watched, and was listed in the top 20 most active stocks&nbsp;on Monday afternoon.Evoke Pharma and its partner, Eversana, found that patients using Gimoti, a nasal version of metoclopramide, experienced significant improvements compared to those using the oral formulation. Patients who received the nasal treatment had reduced healthcare resource use and fewer healthcare visits.Retail sentiment on Stocktwits surged into ‘extremely bullish’ territory (97/100) with ‘extremely high’ (97/100) message volume.Autonomix Medical Inc. (<a class="mention" data-mention="$AMIX" data-symbol-id="AMIX" href="https://stocktwits.com/symbol/AMIX" target="_blank">$AMIX</a>)<figure class="image"><a href="https://stocktwits.com/symbol/AMIX"><img style="aspect-ratio:1271/277;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132518_8d6392edf1.png" alt="Screenshot 2024-10-28 132518.png" width="1271" height="277"></a><figcaption>Autonomix Medical's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Shares of Autonomix skyrocketed by more than 90% on Monday morning following the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/autonomix-stock-rallies-on-strong-trial-results/cJ2rlAHRJf">announcement of positive results from its clinical trial</a> aimed at alleviating pain in pancreatic cancer patients.&nbsp;The stock became the second-highest trending on Stocktwits, just behind Trump Media &amp; Technology Group Corp. ($DJT), and was listed among the top 10 most watched stocks of the day.Retail sentiment on Stocktwits surged to ‘extremely bullish’ (97/100) with chatter escalating into ‘extremely high’ (97/100) territory.For updates and corrections email newsroom@stocktwits.com.Read more: <a href="https://stocktwits.com/news-articles/markets/equity/mstr-stock-hits-all-time-high-as-btc-crosses-68000/cJ2rj2hRJ9">MicroStrategy’s Bitcoin Holdings Drive Historic High: Retail Unfazed</a>

Retail is most bullish on these stocks today | Source: Pexels

Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention

Retail sentiment was particularly strong for healthcare stocks today, as Monte Rosa, Autonomix, and Evoke Pharma each announced positive developments regarding their respective innovations.

Shares of nano-cap specialty biopharma Evoke Pharma, Inc. ($EVOK) skyrocketed on Monday following its presentation of positive data for its lead drug Gimoti as a treatment option for diabetes gastroparesis.Solana Beach, California-based Evoke said on Monday that it along with its Eversana, a provider of global commercial services to the life sciences industry, presented data for GLP-1 users with diabetic gastroparesis using Gimoti at the 2024 American College of Gastroenterology annual meeting.The real-world retrospective study that evaluated the impact of Gimoti showed significant reductions across a collection of outcomes observed in patients treated with Gimoti, a nasal formulation of metoclopramide, versus oral formulation of the same, Evoke Pharma said.Patients taking nasal formulation had reduced healthcare resource utilization, and fewer healthcare visits."Our goal is to provide data regarding Gimoti as supportive care for diabetic gastroparesis for those also on GLP-1 agonists. This study, combined with the earlier real-world data presented at key conferences, reinforces GIMOTI's potential to improve outcomes for patients and reduce the overall financial burden on the healthcare system,” said Matt D’Onofrio, CEO of Evoke Pharma.<figure class="image"><a href="https://stocktwits.com/symbol/EVOK"><img style="aspect-ratio:632/132;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/evok_sentiment_973d4ea465.png" alt="evok-sentiment.png" width="632" height="132"></a><figcaption>EVOK sentiment and message volume October 28, 2024, as of 11:05 am ET | Source:&nbsp;Stocktwits</figcaption></figure>Amid the stock rally, retail sentiment toward the stock improved from ‘neutral’ a day ago to ‘extremely bullish’ (97/100) on Monday morning, with message volume spiking to ‘extremely high.’Some among the retail crowd cautioned against selling the stock and said it is worth much more than the level at which it currently traded.<stembedurl>https://stocktwits.com/Shieldsstocks/message/590294090</stembedurl>Gimoti received FDA approval as an option of alleviating symptoms in adults with acute and recurrent diabetic gastroparesis in June 2020.In the second-quarter ended June 30, 2024, Gimoti sales climbed 126% year-over-year and 47% sequentially to $2.55 million. At that time, the company revised up its 2024 net sales guidance from $11 million-$12 million to $14 million, citing the trend seen in the first half of the year.As of 11:05 a.m. ET, Evoke Pharms shares climbed 67.55% to $3.58.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/five-magnificent-seven-companies-are-due-to-release-their-quarterly-score-cards-this-week/cJ2riJORJJ">Apple, Microsoft, Google, Meta, Amazon: How’s Retail Feeling About These Big Tech Stocks Ahead Of Earnings This Week?</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

Evoke pharma presentation of real-world data for Gimoti at a conference sent its shares soaring.

Evoke Pharma's Retail Sentiment Soars As Stock Rockets On Promising Real-World Data For Gastric Disorder Drug

The real-world retrospective study that evaluated the impact of Gimoti showed significant reductions across a collection of outcomes observed in patients treated with Gimoti.

Evoke Pharma Stock Is Soaring Monday: What's Going On?

Evoke Pharma Inc (NASDAQ:EVOK) shares are trading higher Monday after the company presented GLP-1 data for users with diabetic gastoparesis using GIMOTI showing statistically significant...

Why Evoke Pharma (EVOK) Stock Is Volatile

Evoke Pharma shares were trading lower by 21.4% during Tuesday's session. The company announced a 1-for-12 reverse stock split of its common stock.
read more...

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It also develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Evoke Pharma Inc

$HOOD

$ELF

$DUOL

$CELH

Which of these post-earnings decliners are you most interested in buying?

EVOK
Evoke Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest EVOK News

EVOKEvoke Pharma Inc